Details for New Drug Application (NDA): 202692
✉ Email this page to a colleague
NDA 202692 describes OFLOXACIN, which is a drug marketed by Bedford, Altaire Pharms Inc, Alvogen, Amneal, Apotex Inc, Bausch And Lomb, Caplin, Epic Pharma Llc, Fdc Ltd, Mankind Pharma, Sandoz, Sentiss, Somerset, Hikma, Somerset Theraps Llc, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Ltd, Ranbaxy Labs Ltd, and Teva, and is included in twenty-nine NDAs. It is available from thirty-one suppliers. Additional details are available on the OFLOXACIN profile page.
The generic ingredient in OFLOXACIN is ofloxacin. There are seventy-eight drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the ofloxacin profile page.
The generic ingredient in OFLOXACIN is ofloxacin. There are seventy-eight drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the ofloxacin profile page.
Summary for 202692
| Tradename: | OFLOXACIN |
| Applicant: | Altaire Pharms Inc |
| Ingredient: | ofloxacin |
| Patents: | 0 |
Suppliers and Packaging for NDA: 202692
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| OFLOXACIN | ofloxacin | SOLUTION/DROPS;OPHTHALMIC | 202692 | ANDA | Altaire Pharmaceuticals Inc. | 59390-140 | 59390-140-05 | 5 mL in 1 BOTTLE, DROPPER (59390-140-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.3% | ||||
| Approval Date: | Apr 29, 2013 | TE: | AT | RLD: | No | ||||
Complete Access Available with Subscription
